SCHEMBL12481966

SCHEMBL12481966

CCC(=O)C(NS(=O)(=O)c1ccc(C)cc1)c1ccccc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.57
▸ KMT2A Q03164 2/20 0.57
▸ MEN1 O00255 1/20 0.57
▸ HPN P05981 2/20 0.56
▸ PLAU P00749 1/20 0.56
▸ CA2 P00918 2/20 0.50
▸ CA7 P43166 1/20 0.50
▸ GAA P10253 2/20 0.49
▸ KDM4E B2RXH2 1/20 0.49
▸ GLA P06280 1/20 0.49
▸ MAPT P10636 1/20 0.49
▸ HTT P42858 1/20 0.49
▸ NPSR1 Q6W5P4 1/20 0.49
▸ ATM Q13315 1/20 0.49
▸ L3MBTL1 Q9Y468 1/20 0.49
▸ KCNA5 P22460 2/20 0.48
▸ CYP1A2 P05177 1/20 0.48
▸ CYP3A4 P08684 1/20 0.48
▸ CYP2D6 P10635 1/20 0.48
▸ CYP2C9 P11712 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2161104 0.85 ALDH1A1 (0.62) ALDH1A1KMT2AMEN1HPNPLAU
SCHEMBL1000596 0.85 ALDH1A1 (0.62) ALDH1A1KMT2AMEN1HPNPLAU
SCHEMBL2161085 0.85 ALDH1A1 (0.62) ALDH1A1KMT2AMEN1HPNPLAU
SCHEMBL9611224 0.85 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1HPNPLAU
SCHEMBL9611222 0.85 ALDH1A1 (0.56) ALDH1A1KMT2AMEN1HPNPLAU
SCHEMBL15368932 0.84 ALDH1A1 (0.60) ALDH1A1KMT2AMEN1HPNPLAU
SCHEMBL15338715 0.83 ALDH1A1 (0.59) ALDH1A1KMT2AMEN1HPNPLAU
SCHEMBL8441578 0.83 ALDH1A1 (0.54) ALDH1A1KMT2AMEN1HPNPLAU
SCHEMBL4059198 0.82 ALDH1A1 (0.51) ALDH1A1KMT2AMEN1HPNPLAU
SCHEMBL15213278 0.81 MMP9 (0.63) ALDH1A1CA2CA7GAAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8440706-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2013-05-14 — — US disclosed
US-7985762-B2 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2011-07-26 — — US disclosed
US-20100272681-A1 Inhibitors of Serine Proteases VERTEX PHARMACEUTICALS INCORPORATED (US) 2010-10-28 — — US disclosed
US-20070179167-A1 Inhibitors of serine proteases VERTEX PHARMACEUTICALS INCORPORATED 2007-08-02 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070179167-A1 Inhibitors of serine proteases PRSS1, PRSS3, PRSS2 ALDH1A1 1374/4885KMT2A 3222/4885MEN1 2930/4885
US-20100272681-A1 Inhibitors of Serine Proteases SERPINB1, PRSS1, SPINT2 ALDH1A1 2219/4885KMT2A 3161/4885MEN1 4026/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback